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Heterozygous deletions of chromosome 7 are frequent in myelodysplastic syndrome (MDS) and acute
myeloid leukemia (AML). In this issue of Cancer Cell, Chen and colleagues identify MLL3 as a novel haplo-
insufficient tumor suppressor on 7q that, in combination with NF1 suppression and TP53 deficiency, medi-
ates MDS and AML phenotypes in mouse and human systems.Heterozygous deletions or losses of
chromosome 7 (7/7q-) are frequently
observed in patients with myelodysplas-
tic syndrome (MDS) and acute myeloid
leukemia (AML) and are associated with
chemoresistance and poor outcome. Pre-
vious studies have examined the genetics
and functional genomics of patients with
7/7q-, including at the stem cell level,
and identified genes involved in disease
pathogenesis (Wong et al., 2010; Pella-
gatti et al., 2010; Barreyro et al., 2012;
McNerney et al., 2013). However, no
definitive single haploinsufficient tumor
suppressor in this region has thus far
been functionally validated in its capacity
to induce overt MDS or AML in an experi-
mental model. Experimental heterozy-
gous deletion of one of the commonly
deleted regions failed to result in overt
myeloid disease in mice (Wong et al.,
2010), and previous studies did not detect
biallelic inactivation of any candidate
tumor suppressors (Curtiss et al., 2005).
Recent advances in our knowledge of
the multi-step pathogenesis of myeloid
malignancies and functional work on co-
occurring disease alleles have highlighted
limitations in the study of single candi-
date alleles and shown striking disease
phenotypeswhencombinatorial allelic ge-
notypes were examined (Jan et al., 2012;
Abdel-Wahab et al., 2013). This leads to
the hypothesis that haploinsufficiency of
candidate genes in regions commonly
deleted in cancers (e.g., here, on chromo-
some 7) may have detectable tumor sup-pressing activity only in the context of
other cooperating genetic events.
In an approach to identify and experi-
mentally interrogate such context-depen-
dent combinatorial candidate tumor
suppressors in 7/7q- AML, Chen et al.
(2014; in this issue of Cancer Cell)
analyzed their own and other published
genomic data on AML patients and
focused on one particular candidate 7q
tumor suppressor, the mixed lineage leu-
kemia 3 (MLL3) gene. Chen et al. (2014)
noticed that haploinsufficiency of MLL3
(by deletion of 7q, loss of chromosome
7, orMLL3 nonsense mutation) frequently
co-occurred with monoallelic deletion of
the neurofibromin 1 (NF1) gene in combi-
nation with TP53 inactivation. MLL3 is a
member of the MLL family (comprising
other members that are frequently rear-
ranged in human leukemias) and contains
a SET domain that can transfer a methyl
group to lysine 4 of histone H3. In addi-
tion, MLL3 can mediate histone H3 K27
demethylation through a physical interac-
tion with the histone H3 demethylase
UTX. NF1 is a potent suppressor of RAS
oncogenic signaling, and its inactivation
has been shown to induce a myeloprolif-
erative phenotype (Le et al., 2004).
To functionally interrogate poten-
tial leukemogenic cooperativity among
MLL3, NF1, and TP53, Chen et al. (2014)
leveraged several elegant and comple-
mentary model systems. First, they used
retroviral delivery of short hairpin RNAs
(shRNAs), directed against Mll3 or Nf1Cancer Cel(shMll3 or shNf1) and labeled with
different fluorophores, into p53-deficient
hematopoietic stem and progenitor cells
(HSPCs), followed by syngeneic trans-
plantation. They observed striking coop-
erativity in the induction and progression
of an aggressive transplantable AML
when Mll3 and Nf1 were simultaneously
suppressed (Figure 1). Importantly, sup-
pression of Mll3 and Nf1 in wild-type
HSPCs was not leukemogenic, and
shMll3 alone in p53/ HSPCs did not
accelerate p53-induced thymic lym-
phomas, demonstrating that indeed the
combinatorial suppression of all three
tumor suppressors (i.e., Mll3, Nf1, and
p53) is required for AML initiation. Anal-
ysis of gene expression in the formed
AML cells showed residual expression
levels of both Mll3 and Nf1 at about 50%
of their levels in controls. As the initially
transduced HSPC populations were poly-
clonal, this indeed suggested that cells
with intermediate Mll3 and Nf1 knock-
down have a selective advantage during
leukemogenesis. To further support their
hypothesis of Mll3 haploinsufficiency in
AML pathogenesis, Chen et al. (2014) uti-
lized in vivo CRISPR/Cas9 genome edit-
ing technology to disrupt Mll3. Strikingly,
and consistent with shRNA knockdown
experiments, CRISPR/Cas9 targeting
of Mll3 in shNf1;p53/ cells led to dis-
ease acceleration and AML development
as opposed to T-ALL development in
recipient mice transplanted with cells of
the same background, but transducedl 25, May 12, 2014 ª2014 Elsevier Inc. 555
Figure 1. Leukemogenic Cooperation of Mll3 and Nf1 Haploinsufficiency in a p53-Deficient
Background
Adoptive transfer of lentivirally transduced hematopoietic stem and progenitor cells (HSPCs) into
syngeneic recipient animals leads to an AML recapitulating hallmarks of human 7/7q- AML, in contrast
to thymic lymphoma induced by p53 deficiency only.
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a noncoding region. Importantly, while
CRISPR/Cas9-directed mutagenesis can
lead to mutations in one or both
target alleles, sequencing of the induced
AML clones revealed that they were
indeed heterozygous for wild-type Mll3,
suggesting that Mll3 haploinsufficiency
rather than complete loss leads to AML
formation.
Correlative analyses of Mll3 suppres-
sion-induced transcriptional changes
with gene expression data from MDS pa-556 Cancer Cell 25, May 12, 2014 ª2014 Elstients’ CD34+ cells showed high similarity
and a significant enrichment of gene
expression differences found in 7/7q-
MDS versus normal karyotype MDS, sug-
gesting that MLL3 repression is, at least in
part, causing the molecular phenotype
observed in MDS patients’ cells. At the
mechanistic level, Chen et al. (2014) found
reduced trimethylation of H3K4 and
increased trimethylation of H3K27 at the
loci of genes downregulated upon Mll3
suppression. While this is consistent with
an Mll3-dependent epigenetic mecha-evier Inc.nism, further studies will be required to
determine whether this is indeed a direct
effect on histone modifications by Mll3
or Mll3-associated complexes or an
alternative mechanism of transcriptional
regulation.
To study the cellular phenotypes medi-
ated byMll3, Chen et al. (2014) examined
shMll3;p53/ HSPCs in comparison to
shRenilla;p53/ controls. They discov-
ered features consistent with human
MDS (Will et al., 2012) transiently pre-
sent in shMll3;p53/ mice: (1) aberrant
morphological features within the mature
myeloid cell compartment, (2) impaired
differentiation at the stem cell level
concomitant with an increase in long-
term HSCs, and (3) increased prolifera-
tive activity of immature cKit+ cells. These
findings indicate that MLL3 plays an
important role in HSC differentiation,
but requires cooperating events for sus-
tained MDS disease and progression to
overt AML.
Chen et al. (2014) furthermore suggest
that modest transcriptional changes in
HSC, even if they lead to transient func-
tional alterations, can determine transfor-
mation of a particular lineage at a later
stage or lead to a switch of the lineage
affected by transformation (a phenome-
non also observed in human leukemias
at relapse though infrequently). Further
studies will be required to determine
the step-wise temporal acquisition of ab-
errations and their precise cell type(s) of
occurrence.
Lastly, Chen et al. (2014) studied
the role of Mll3 in resistance to
chemotherapy. They observed that mice
harboring shMll3;shNf1;p53/ (MNP)
AML were highly resistant to cytarabine
plus doxorubicin therapy, which resem-
bles the current standard in induction
chemotherapy used for AML treatment.
Furthermore, MLL3 suppression in a
chemosensitive type of leukemia (AML1-
ETO;NrasG12D) led to a remarkably
reduced sensitivity to chemotherapy,
suggesting that MLL3 suppression plays
a role in conferring chemotherapeutic
resistance. They went on to show that
MNP AML, as well as several AML cell
lines carrying 7/7q-, are sensitive to
treatment with the bromodomain and ex-
tra-terminal (BET) family inhibitor JQ1,
demonstrating the potential utility of their
model as a tool for the preclinical identifi-
cation and study of novel agents effective
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of AML with poor prognosis. Additional
studies will be required to elucidate a
possible mechanistic link between Mll3
function and the JQ1-mediated, and
potentially Myc-dependent, antiprolifera-
tive effect.
In summary, Chen et al. (2014) have
shown that Mll3 is a haploinsufficient
tumor suppressor on 7q that can act in
conjunctionwithheterozygousNf1deletion
(and possibly other mechanisms of RAS
pathway activation) and Tp53 deficiency
to induce an aggressive transplantable
AML in a murine model. Mll3 suppression
leads to a partial differentiation block at
the level of HSC and MDS-like cellular
and molecular features. Furthermore,
Chenetal.’smousemodel ofMll3 suppres-
sion-induced AML represents an inter-
estingnewtool for thepreclinicalevaluationand mechanistic study of novel pathways
and compounds that may be effective for
the treatment of7/7q- and possibly other
types of chemotherapy-resistant AML.REFERENCES
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TGF-b signaling promotesmetastasis by controlling the expression of downstream target genes. In this issue
ofCancer Cell, Yuan and colleagues discover a novel TGF-b-induced lncRNA, lncRNA-ATB, which stimulates
EMT through sequestering miR-200s and facilitates colonization by stabilizing IL-11mRNA, thus promoting
both early and late steps of cancer metastasis.The transforming growth factor-b (TGF-b)
pathway plays crucial roles during devel-
opment and homeostasis and exerts
strong antiproliferative effects on
normal and premalignant cells. However,
advanced-stage cancers often become
insensitive to the tumor-suppressive
actions of TGF-b. Instead, advanced
cancers benefit from TGF-b’s pro-
found metastasis-promoting effects,
such as epithelial-to-mesenchymal tran-
sition (EMT) induction, angiogenesis
promotion, altered extracellular matrix
deposition, immune suppression, and
increased metastatic colonization (Ikush-
ima and Miyazono, 2010; Massague´,2008). These prometastatic responses to
TGF-b are mediated by a variety of down-
stream effector proteins, including tran-
scription factors (e.g., AP-1, ID1, SNAIL,
SLUG, TWIST, and ZEB1/2), cytokines,
growth factors, and other ligands (e.g.,
ANGPTL4, PTHrP, IL-11, JAGGED1,
PDGF-B, CTGF, and VEGF), matrix pro-
teins and proteases (e.g., TNC, MMPs)
(Ikushima and Miyazono, 2010; Mas-
sague´, 2008), and a growing number of
microRNAs (miRNAs) (Butz et al., 2012).
In recent years, long noncoding RNAs
(lncRNAs), a new class of noncoding
RNAs longer than 200 nucleotides, were
recognized to regulate a wide variety ofphysiological and pathological processes
through diverse mechanisms. For
example, lncRNAs ANRIL and HOTAIR
promote tumor growth or metastasis by
recruiting chromatin-remodeling com-
plexes to alter gene transcription, while
tumor-suppressing lncRNA GAS5 and
tumor-promoting lncRNA HULC act
as decoys for glucocorticoid receptor
and miR-372, respectively (Gutschner
andDiederichs, 2012). Although the diver-
sity and abundance of lncRNAs seem to
rival that of mRNAs in any given cell
type, there is little understanding of
crucial lncRNAs functioning downstream
of the TGF-b pathway. In this issue ofl 25, May 12, 2014 ª2014 Elsevier Inc. 557
